

1 **Title:** Optimisation of a cervical cancer screening model based on self-sampling for human papillomavirus testing

2 **Authors:** María Besó Delgado^{1,2,*}, Josefa Ibáñez Cabanell^{1,2}, Susana Castán Cameo^{1,2}, José Joaquín Mira Solves^{3,4},
3 Mercedes Guilbert Mora^{3,4}, Mercedes Vanaclocha Espí¹, Marina Pinto Carbó¹, Dolores Salas Trejo¹, Oscar Zurriaga
4 Llorens^{5,6}, Ana Molina-Barceló¹.

5 **Author affiliation:**

6 (1) Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research
7 of Valencia Region (FISABIO-Public Health), Valencia, Spain, Ministry of Universal Health and Public
8 Health, Valencia, Spain.

9 (2) Ministry of Universal Health and Public Health, Valencia, Spain.

10 (3) Department of Health Psychology. Miguel Hernández University, Elche, Spain.

11 (4) Foundation for the Promotion of Health and Biomedical Research of the Valencia Region, FISABIO,
12 ATENEA Investigación. Alicante-Sant Joan Health Department. Alicante, Spain.

13 (5) Preventive Medicine and Public Health Department. Food Science, Toxicology and Forensic Medicine.
14 University of Valencia. Valencia. Spain.

15 (6) Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP). Spain.

16

17

18 ***Corresponding author**

19 Email: mariabesodelgado@gmail.com (MBD)

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

51 Abstract

52 The use of self-sampling devices in population-based cervical cancer screening programmes (CCSP) is both an
53 opportunity and a challenge in terms of implementation.

54 **Objective:** To understand the expectations, preferences, and difficulties perceived by women as regards different
55 screening models and self-sampling devices, with the aim of identifying strategies to achieve high CCSP participation
56 rates.

57 **Methods:** This study is based on qualitative research techniques, consisting of an individual interview using a
58 questionnaire with semi-structured questions, followed by a group interview. Sessions were held simultaneously
59 with 4 groups (7-8 women aged between 35 and 65). Women assessed various aspects of the programme
60 (information dissemination, invitation, receipt of results, etc.) and five self-sampling devices.

61 **Results:** If screening were carried out via self-sampling, 96.4% of women said they would take the test. Most
62 women preferred to receive information on the CCSP or return their samples at their health centres (86.2% and
63 86.2%), and the most popular method for receiving both the programme invitation and results is by SMS (58.6%,
64 65.5%).

65 Simplicity and ease of use are the key features of the device accepted by the largest number of women, the
66 FLOQSwab. Another highly rated feature is the attractive design of the Evalyn Brush, as this was the preferred
67 device of the largest number of women.

68 The existence of other screening programmes that use self-sampling devices (the colorectal cancer prevention
69 programme) is an opportunity as regards acceptance of this new programme. Some women are unsure of how to
70 use the devices correctly.

71 A large number of women accept self-sampling and reveals significant differences in the degree of acceptance of
72 different self-sampling devices. Selecting the most accepted device is key to achieving high CCSP participation rates,
73 and these programmes should be accompanied by adapted information campaigns to reach the most vulnerable
74 groups and ensure equity.

75 **Keywords:** Cervical Cancer, Screening, HPV, self-sampling, qualitative, participation, screening program

76 List of abbreviations:

77 HPV: Human Papillomavirus

78 CCSP: Population-based cervical cancer screening programmes

79 IARC: International Agency for Research on Cancer

80

82 Introduction

83 Cervical cancer is the fourth most common cancer affecting women in terms of both incidence and
84 mortality, with an estimated global mortality rate of 7.3 per 100,000 per year in 2020, according to the International
85 Agency for Research on Cancer (IARC)[1]. In most cases, these cancers are secondary to persistent high-risk human
86 papillomavirus (HPV) infection.

87 Carcinogenesis is a multi-step, long-term process in which both genetic and morphological changes occur
88 in the cells of the cervix. As population-based cervical cancer screening programmes are widely proven to be cost-
89 effective and make it possible to detect and treat lesions at an early stage, their implementation is included in
90 European Commission recommendations [2-3] and they are a fundamental tool for preventing cervical cancer.
91 However, many European countries, such as Spain, have opportunistic cervical cancer screening programmes [4-5]
92 that reach just a small section of the target population and achieve limited benefits, while also generating
93 inequalities. Countries face the challenge of converting these opportunistic programmes into population-based
94 programmes.

95 Moreover, in recent years the recommendations of this screening programme have been modified. Firstly,
96 HPV detection has been incorporated as a primary screening test to replace conventional cervical cytology testing,
97 as recommended by numerous organisations and agencies [2, 6, 7, 8]. With the acceptance and approval of this
98 new primary test, the use of self-sampling devices, which allow women to collect an HPV testing sample at home,
99 has been researched and approved [9]. The effectiveness of these tests has been widely demonstrated [10,11] and
100 the WHO has recommended their use in cervical cancer screening, as it believes they will lead to greater acceptance
101 of and participation in screening programmes [12-14]. Thus, in line with European recommendations, in 2019 the
102 Spanish Ministry of Health determined [15] the need to implement population-based cervical cancer screening
103 programmes throughout the country and established HPV testing as a screening test for women aged 35 to 65. The
104 country's various regions are assessing the use and implementation of self-sampling devices.

105 Therefore, given that high target population participation and coverage rates are necessary to achieve the
106 desired programme effectiveness, strategies adapted to the specific sociological, cultural, and healthcare
107 characteristics of each region and community must be designed prior to the implementation of a population-based
108 programme [16]. The characteristics of the population and the programme (such as the type of screening test used,
109 the way the target population is invited, uptake, or information campaigns) are a key factor in the results [17]. For
110 this reason, to reach the established goals, it is fundamental to study the population where the programme is to be

111 implemented in order to find out their preferences, needs, barriers, or insecurities regarding different models of
112 invitation, uptake, information, screening tests, etc., thus enabling equitable access to the programme [18].

113 As regards selecting strategies to optimise screening programmes, the incorporation of new technologies
114 (mobile applications or social networks) to inform, invite, and ensure uptake of the target population is an
115 opportunity for improvement in new screening models. Some of these tools are already being used and tested to
116 determine how they could improve participation in population-based cancer screening programmes [19,20], and
117 they must be assessed when implementing a new programme.

118 In this line, and given that primary screening test uptake is of the utmost importance in achieving high
119 participation rates, the assessment of new self-sampling devices is essential. Even though numerous studies show
120 that they are greatly accepted by women [21,22] and they are included in the WHO Consolidated Guideline on Self-
121 Care Interventions for Health [23], there are limited studies assessing the type of device that women prefer from
122 the wide range available on the market [24]. However, their format and mode of use can be a critical factor in
123 population participation, and recently published studies have highlighted the need for additional research
124 examining women's preferences [24]. This will be essential to reach the WHO's target that 70% of women should
125 undergo cervical cancer screening by 2030 [25].

126 As a population-based cervical cancer programme will soon be implemented in the Valencia Region, the
127 purpose of this study was to find out the expectations, preferences, and difficulties perceived by women as regards
128 different ways of inviting them to participate in the prevention programme, uptake and self-sampling devices for
129 HPV testing, with the aim of detecting strategies to achieve high participation rates in this region's population-based
130 cervical cancer prevention programme.

131 **Materials and Methods**

132 The study was based on qualitative research techniques.

133 **Ethics statement**

134 All methods of the study were performed in accordance with the Declaration of Helsinki and was approved by the It
135 was approved by the Committee of Ethics and Research Integrity of Miguel Hernández University of Elche
136 (reference no. AUT.DPS.JMS.01.21, date 30/09/2021).

137 Participants were informed and subsequently signed a consent form to participate in the study and agreed to the
138 sessions being recorded.

139 **Design and Participants**

140 We worked with a total of 29 women. The following inclusion criteria were used for non-random
141 selection: accept to participate, be aged between 35 and 65, live in the Region of Valencia, and represent different
142 ethnicities. We created mirror groups by working in parallel with 4 sets of 7–8 women who had a similar profile in
143 terms of age, educational level, and professional activity.

144 The women were selected using the snowball technique, ensuring that working and discussion groups
145 were sufficiently representative in terms of age, education, professional activity and ethnicity.

146 Sessions were conducted with the four groups simultaneously, lasted 120 minutes each, and were
147 recorded with the consent of the participants. The anonymity and confidentiality of the recorded material was
148 guaranteed. The process was led by researchers with extensive experience in conducting qualitative studies.

149 **Interventions and content**

150 The first phase of the session involved an individual interview with each woman, where they anonymously
151 completed a **questionnaire of semi-structured questions** in writing using a workbook. This questionnaire was
152 carried out individually and anonymously to prevent the participants from influencing each other. In the second
153 phase, **group interviews** were used to confirm trends or reveal any possible points of interest that had not been
154 addressed.

155 During the first phase, the women were presented with a draft programme information leaflet regarding
156 the new cervical cancer screening programme, which included the use of self-sampling devices as a screening
157 method for women aged 35 to 65. These devices would be received by post and returned in health centres. Women
158 responded to questions about the content of information materials, their preferred information channels, and
159 details of the screening model and its circuits at each stage (method of invitation, acceptance and use of the self-
160 sampling device, method of communicating results, etc.). Multiple-choice questions were used for this purpose.
161 They also answered questions about their previous participation in the opportunistic cervical cancer screening
162 programme or whether they were aware of other screening programmes.

163 Subsequently, the self-sampling devices were distributed to the women in a sequence and they
164 individually assessed each one without influencing the views of the other women in the group. Manufacturer
165 instructions on how to use the device were provided. Five tests were assessed in this study (figure 1): (Device A)
166 FLOQSwab® 552C.80 (Copan Diagnostica Inc.), (Device B) Evalyn® Brush (Rovers Medical), (Device C) Aptima
167 Multitest Swab® (Hologic), (Device D) IUNETEST® (Self Test Technologies, S.L), and (Device E) Qvintip® (Aproxix). They
168 were selected based on their previous use in screening programmes and their ease of use. When the devices were
169 distributed, the researchers provided usage instructions and the participants then answered two questions

170 regarding whether they thought they were easy to use and if they would use them at home, plus an open-ended
171 question to explain their opinions. The devices were presented to the 4 groups in a random order. After the
172 individual assessment, the devices were compared and the women selected which one they thought was the easiest
173 to use, which one they felt most comfortable or confident using, which one they considered the best and worst, and
174 which three devices they would prefer to use.

175 [Fig 1. Self sampling devices assessed].

176 *[Fig 1 legend. (Device A) FLOQSwabs is a plastic swab with a rounded tip made of nylon fibers, which must be*
177 *removed from the tube containing it by rotation, inserted into the vagina up to the indicative line and reintroduced*
178 *into the tube; (Device B) EvalynBrush is a plastic device, with a brush at one end and a plunger at the other end, with*
179 *a cap. It must be inserted up to the side wings, rotate the plunger 5 times and put the lid on; (Device C) Aptima*
180 *Multitest Swab consists of a cardboard swab with a rounded cotton tip and a tube with a liquid medium. After*
181 *inserting the swab into the vagina up to the indicative line, it must be inserted into the liquid medium and broken to*
182 *leave the tip inside; (Device D) IUNETEST is a plastic tube with a cap at one end and a rotary plunger at the other. To*
183 *use it, it must be inserted, the plunger pushed and rotated, and finally the lid is placed; (Device E) Qvintip contains a*
184 *test tube and a wand with a hooked tip at one end. For use, after inserting and rotating the wand in the vagina, the*
185 *plastic tip must be inserted into the tube, resting on its walls to unhook it of the wand and leave it inside].*

186 During the group interview, a structured discussion was opened in which the women talked about the
187 new screening programme, the content of the information leaflet, and the self-sampling devices. Data were
188 triangulated to analyse similarities and differences between the groups. Interviews were ended once a sufficient
189 level of information saturation had been reached.

190 Analysis

191 A descriptive analysis was created showing frequencies and percentages relative to the different options
192 provided in the closed-ended questions. For the open-ended questions, the session transcripts were used to
193 identify and classify the different ideas into mutually exclusive categories. The number of different ideas was
194 counted, as well as the number of times each of these ideas was repeated, as a measure of contribution intensity.
195 Two researchers assigned the ideas to categories. A third researcher was consulted if they were unsure or unable to
196 reach an agreement, and a consensus was reached regarding the assigned category for all ideas.

197 When analysing the group interview results, the spontaneity of the women's ideas was taken into
198 account. This refers to the number of women who independently proposed the same idea. The data was then
199 triangulated to analyse similarities and differences between participants and groups of participants.

200 Results

201 A total of 29 women participated in the study. In terms of educational level, 44.8% (13 women) had completed
202 university studies, 27.6% (n=8) had completed vocational training studies, and the rest had completed compulsory
203 secondary education. The average age was around 50. A total of 96.6% of women (n=28) had had a cervical cytology
204 test, and 86.2% (n=25) had had a cervical cytology test every 3 years or less. In addition, 79.3% (n=23) said they
205 were aware of other cancer prevention campaigns (breast and colon).

206 CCSP assessments

207 When assessing different aspects of the programme (figure 2), it was found that women preferred to receive
208 information on the programme from health centres (86.2%), from breast cancer prevention units (75.9%), from
209 women's associations (69%), by post (51.7%), and by SMS (44.8%), or through email, citizens' associations, and work
210 centres (34.5% overall). In relation to the tools for contacting the population, the women preferred to be invited to
211 participate in the programme by SMS, selected by 58.6%, or by post with 48.3%, while the mobile application of the
212 Regional Ministry of Health was accepted by 24.1% of women. Similarly, the majority chose to receive test results
213 by SMS (65.5%), while 37.9% preferred to receive results by post and 20.7% through the mobile application. Once
214 the sample had been collected, they preferred to return their self-sampling devices in health centres (86.2%), as
215 opposed to pharmacies (17.2%) or hospitals (3.4%). In relation to screening by self-sampling, 96.4% stated that they
216 would take part if this screening method were used.

217 [Fig 2. Preferences relating to different general aspects of the screening program].

218 Individual device assessment

219 Overall, 93.1% of women considered that Device A was easy to use, 79.3% Device D, 69% Device B and
220 Device C, and 62.1% Device E. The most widely accepted devices for home use were Device A and Device D, both
221 with 75.9% acceptance, followed by Device B (72.4%), Device E (48.3%), and Device C (37.9%). The results are
222 shown in figure 3.

223 [Fig 3. Results of the individualized assessment of devices according to ease of use and their acceptance for use at
224 home.]

225 Various **positive aspects** were highlighted in the open-ended question (data shown in table 1). One
226 example is simplicity and ease of use, which was mentioned by 15 women in relation to Device A and 13 women in
227 relation to Device D. Another positive aspect pointed out by the women was that the device was not perceived to

228 be invasive, as indicated by 4 women in relation to Device A, Device C, and Device D. The attractive design of Device
 229 B was mentioned by 6 women. In addition, 4 women considered that the familiar (tampon-like) appearance of
 230 Device D was positive. The participants identified the highest number of different positive aspects in relation to
 231 Device A and Device B, with a total of 11 each. The total number of times that these positive aspects were
 232 mentioned overall was highest in relation to Device A, with a total of 30. The most frequently indicated **negative**
 233 **aspects** were difficulty of use and operation, which were mentioned by 9 women in relation to Device C and 7 in
 234 relation to Device E. Discomfort was another aspect mentioned by 5 women in relation to Device D and Device E,
 235 and by 4 women in relation to Device B. A total of 7 women highlighted the high risk of sample contamination with
 236 Device E due to the usage method. Fragility was rated as a negative aspect by 5 women in relation to Device A and
 237 by 3 in relation to Device C. The women identified the highest number of different negative aspects in relation to
 238 Device E (10), Device B (8), and Device C (8). The total number of times that these negative aspects elements were
 239 mentioned overall was highest in relation to Device C (26), Device E (22), and Device B (18).

240 Table 1. Positive and negative evaluations of the self-sampling devices collected from the open-ended question.

	FLOQSwabs	EvalynBrush	Aptima Multitest Swab	IUNETEST	Qvintip
Positive aspects					
Simplicity of the device, ease of use	15	4	5	13	5
non-invasive device	4	3	4	4	2
Safe, inspires confidence	2	3	1	-	3
Family mechanism (similar to a tampon)	-	-	-	4	1
Mark indicating the depth of penetration	2	-	1	-	-
Attractive design	-	6	-	-	-
Total (Different items/totals)	11/30	11/23	8/15	9/27	5/12
Negative aspects					
Use and complex handling	4	4	9	3	7
Uncomfortable	2	4	-	5	5
Sudden steps, which requires strength	-	4	2	-	1
High risk of sample contamination	-	1	3	-	7
Fragile	5	-	3	-	-
Dangerous	-	-	4	-	-
Unhygienic	-	-	3	-	-
Low trust, unsure	-	-	-	-	4
Total (Different items/totals)	5/11	8/18	8/26	5/9	10/22

241 Table 1 Legend. Due to the great diversity of aspects mentioned, this table includes the most relevant, having left
242 some aspects out of the table, which is why the total number of elements does not correspond in many cases to the
243 total number of the list.

244 **Comparative device assessment**

245 The most voted devices were as follows: for ease of use, Device A (52.38%) and Device D (28.57%); for
246 feeling of confidence transmitted, Device B (51.72%) and Device A (24.14%); for comfort of use, Device B (35.71%)
247 and Device A (25.0%). When asked to select the device they liked the most, Device B (31.03%) and Device A
248 (27.59%) received the most votes, and when asked to select the one they liked the least, Device C (28.57%), Device
249 E (25.0%), and Device B (21.43%) received the most votes. The results are shown in figure 4. Finally, when
250 participants were asked to select the three self-sampling devices they would use at home, Device A (22), Device B
251 (20), and Device D (18) received the most votes, while Device C and Device E were selected by 13 and 11 women,
252 respectively (results not shown in tables).

253 [Fig 4. Results of the selection of a device for its greater ease, reliability, comfort and more and less appreciated].

254 **Self-sampling assessment synthesis**

255 Thus, Device B is preferred by some women, and Device A is accepted by the greatest number of women. Simplicity
256 and ease of use are the key features highlighted in relation to Device A, the device with the highest number of
257 votes. The attractive design of Device B was mentioned as a positive aspect and, although it was some women's
258 preferred option, others considered that it was uncomfortable to use. Device C and Device E were accepted by the
259 lowest number of women. The self-sampling process of devices with lower levels of acceptance included
260 intermediate steps or steps perceived as complicated due to their rough or dangerous nature. Examples are the
261 need to insert the sample into a liquid medium in the case of Device C, or the painstaking process of removing the
262 crimped tip from the sampler stick in the case of Device E. Although Device D was not singled out due to any
263 negative aspect in particular, it did not score well in the comparative assessment.

264 **Group session assessment**

265 Finally, ideas that came up in the group session revealed many positive attitudes towards a new screening
266 programme based on self-sampling devices (n=9). The existence of another screening programme based on a self-
267 sampling device (faecal occult blood screening devices used in the colorectal cancer prevention programme) is seen
268 as an opportunity (n=3). Some verbatim examples are as follows: "*If you can take the self-sample test for the colon
269 cancer prevention programme, you can do this one, too*", "*I think it's great that everyone takes their own sample*",
270 "*...we're already familiar with the colon cancer programme...or know someone that has taken part... I think it will be
271 much easier to implement the cervical cancer prevention programme*". In addition, home testing is considered

272 positive due to the speed and practicality (n=1) of this method, as well as the possibility of including more
 273 vulnerable groups (n=2). *“People of different ethnicities or races will have a better chance of being screened”, “it can*
 274 *reach more people and free up in-person appointments”, “you don’t have to wait, because sometimes you can’t be*
 275 *bothered to go to the gynaecologist to get it done”*. They believed that this programme will be accepted, on the one
 276 hand, due to women's increased awareness of screening (n=2) and, on the other hand, because they consider that
 277 people will eventually adapt to the new measures (n=1).

278 Ideas were provided for improving the content of the message in information leaflets or possible
 279 campaigns, showing the need for a stronger message (n=6): *“include information on mortality”, “...more forceful*
 280 *messaging”*.

281 Perceived fears centred on uncertainty as regards the reliability of self-sampling (n=4): *“maybe we won’t*
 282 *do the test correctly and the results aren’t right”, “questions about precision: how many centimetres it should be,*
 283 *counting the turns, etc.”, “uncertainty of not going to a clinic/hospital and not noticing any other illnesses or*
 284 *mistakes with self-sampling”*. The feeling of a lack of protection for certain age groups or groups that might not be
 285 able to use the self-sampling device due to a lack of knowledge about their own bodies also generated uncertainty.
 286 Here are some verbatim statements: *“feeling of lack of protection and information for older people”, “due to their*
 287 *age, they prefer traditional screening”, or “many women do not have sufficient knowledge of their own bodies to do*
 288 *this themselves”*. The statements grouped by theme are shown in table 2.

289 Table 2. Verbatim statements provided in the group session to assess the cervical cancer screening programme and
 290 self-sampling, grouped by category.

Categories	Verbatim statements
Positive attitude to the new self-sampling programme (9)	Previous positive experience with the colon test. <i>“It’s something that gets sent to your home, that you have to do, you read the instructions, you follow them, you take the sample, you take it to the health centre and then they send you the letter” “You’re in perfect health” or “no, bad luck”. “If you are not well, the doctor calls you. If you can take the self-sample test for the colon cancer prevention programme, you can do this one, too. I think it’s great that everyone takes their own sample” (3)</i>
	People of different ethnicities or races will have a better chance of being screened. It can reach more people and free up in-person appointments. It can also be useful to monitor how often you have had a Pap smear. (2)
	Increased awareness of HPV (2). <i>“I think women are more aware that we could get cancer or the human papilloma virus. So, I get the impression that we won’t think it’s strange to get the device and take the self-sample at home”. “I think it will be easy and quick to set up for all the reasons that the others are saying. We’re already familiar with the colon cancer programme or know someone that has taken part. I think it will be much easier to implement the cervical cancer prevention programme”</i>
	It is practical. <i>“You don’t have to wait, because sometimes you can’t be bothered to go to the gynaecologist to get it done” (1)</i>
Content of the message in information materials (6)	A matter of time and practice to adapt to new measures (1)
	More forceful messaging (2)
	Messages must be very forceful to ensure that the programme doesn’t generate doubts (1)
	Mention the reasons for the screening programme with health statistics: mortality, incidence (2)

	“For example, just because you don't have any symptoms doesn't mean you are unhealthy, you could have HPV and develop cervical cancer in the future” (1)
Lack of information on the programme itself (5)	More information if restricted to cervical cancer or other diseases (2)
	The only doubt is where to drop it off at the health centre (1)
	It may give rise to doubts (1)
	Provide information on the possible infections and discomfort that it can cause (1)
Reliability of self-sampling (4)	Maybe we won't do the test correctly and the results aren't right (1)
	Uncertainty about whether you have done it right (1)
	Questions about precision: how many centimetres it should be, counting the turns, etc. (1)
	Uncertainty of not going to a clinic/hospital and not noticing any other illnesses or mistakes with self-sampling (1)
Feeling of a lack of protection due to insufficient knowledge of the body or not being in the age range of the programme (5)	It starts at 25 — Younger women are vaccinated against HPV (1)
	Feeling of lack of protection and information for older people (1)
	Due to their age, they prefer traditional screening (1)
	The age from which it is necessary (1)
	Knowledge of the body: “Many women do not have sufficient knowledge of their own bodies to do this themselves” (1)

291 Table 2 legend. The figures in brackets represent the number of times the message was mentioned by women.

292 Discussion

293 The results of this study show numerous opportunities to implement a new population-based cervical cancer
294 screening programme.

295 On the one hand, the use of self-sampling devices is seen as an opportunity as, according to numerous publications
296 [24,26,27] this method is highly accepted by women regardless of the device used. This can also be seen in the
297 results of our study. It is demonstrated by both the high acceptance (96.4% of women) of its use as a screening test
298 and the perceived advantages of use (ease of use, uptake of certain groups, etc.).

299 On the other hand, the existence of established population-based programmes, some of which also include the use
300 of self-sampling tests such as the faecal occult blood test for colorectal cancer screening, could facilitate the
301 acceptance of self-sampling devices for HPV testing, as highlighted by the women in this study.

302 Similarly, the high acceptance of SMS messaging or health system mobile applications as a means of
303 communication, which could be because the COVID-19 pandemic consolidated the use of new technologies in the
304 healthcare environment, could also facilitate the implementation of the programme as well as greater uptake and
305 participation [28,29].

306 Despite the high acceptance of self-sampling, many women are uncertain of their ability to perform the sampling
307 procedure correctly, as has also been pointed out in numerous studies [30-33], or fear that other diseases may not
308 be caught if they do not attend an in-person visit, as per usual practice in opportunistic screening. In addition, while
309 self-sampling may enable vulnerable groups who may find it more difficult to attend an in-person visit to

310 participate, as some studies on the use of self-sampling devices in disadvantaged populations have shown [34], it
311 may also leave certain population groups unprotected. Therefore, to improve women's confidence in self-sampling,
312 public awareness campaigns should include data showing that most women can successfully obtain an adequate
313 sample [18,31,35,36]. Furthermore, information campaigns should also address the lack of protection felt by
314 women in the absence of an in-person visit. To fight against inequality, adapted materials must be created in
315 different languages that are easily understandable for different socio-cultural levels, as pointed out in the WHO
316 Guideline on self-care interventions for health and well-being [17] .

317 As regards the content of these information campaigns and materials, the women in the study believe that it is
318 important to highlight the serious nature of the disease in order to raise public awareness. In this line, the literature
319 indicates that increased risk perception leads to increased participation in screening programmes, and also to
320 increased acceptance of the use of self-sampling devices in the case of cervical cancer [37-38]. Furthermore,
321 appropriate public awareness and information campaigns and educational actions to raise awareness of the
322 importance and impact of cervical cancer prevention have shown to be effective in increasing the acceptance of
323 self-sampling [34,39].

324 The results of this study reveal differences in the degree of acceptance of the different self-sampling models, as was
325 also observed in several studies [31,40,41]. The perceived difficulty when using the device, a feature mentioned in
326 relation to the Qvintip or Aptima Multitest Swab devices, appears to have a significant effect on preference as
327 women liked these [41]two devices the least. An attractive design that is specifically conceived for self-sampling, as
328 described previously, is one of the main features of self-sampling devices that seem to transmit confidence due to
329 their colour or appearance. This quality makes the Evalyn Brush one of the most highly rated devices for some
330 women. However, simplicity is the most important feature of the device accepted by the largest number of women.
331 Other comparative studies [42] also show that women rate this aspect positively in their choice of self-sampling
332 device. Thus, the swab-type device (FLOQSwab) is accepted by the largest number of women, as was observed by
333 Nishimura et al [24]. Although there are not many studies comparing acceptance of different self-sampling devices,
334 there are studies comparing swab and tampon devices which show that the former is more widely accepted, as in
335 this study [43].

336 Some studies do not agree with the results obtained in this study, such as the one carried out by DiGennaro et al,
337 which observed no differences in the degree of acceptance with different types of self-sampling device [44]. This
338 may be because preferences can be influenced by population characteristics (cultural, religious and socio-economic)
339 that determine the degree of acceptance of different devices. Therefore, it may be useful to conduct a pilot study
340 prior to full-scale implementation of the programme, as suggested by Arbyn et al [45].

341 **Limitations.** Nearly half of the participants had completed university studies, which is an over-representation of this
342 group. Another limitation is that the women were able to read instructions on how each of the devices work and
343 operate them, but not to actually use them to take a sample when carrying out their assessment.
344 The lack of published studies comparing different self-sampling devices, as well as the lack of homogeneity of these
345 devices, makes it difficult to compare results.

346

347 **Conclusions**

348 The results of this study provide further insight into preferences regarding self-sampling formats for cervical cancer
349 screening. These results can aid decision-making to implement or improve cervical cancer screening programmes by
350 selecting models that are more widely accepted in order to achieve higher participation rates.

351 The use of new technologies (SMS messaging or specific mobile applications), probably driven by the COVID-19
352 pandemic, stands out as an effective strategy for reaching out to the population in screening programmes.

353 While self-sampling presents an opportunity for the implementation of population-based screening, a screening
354 model based on self-sampling must go hand in hand with powerful and adapted information, education, and public
355 awareness campaigns to build the most vulnerable groups' confidence in self-sampling in order to achieve high
356 participation rates in all population groups and thereby reduce inequalities. Thus, as high participation is a key
357 objective of the programme, appropriate campaigns and educational interventions to raise awareness of the
358 importance and impact of cervical cancer prevention have shown to be effective in increasing the acceptance of
359 self-sampling [34,39].

360 It can be concluded that simplicity is an essential aspect when selecting the self-sampling device. Additionally, given
361 the diverse range of opinions on the different self-sampling models, preferences should be taken into account to
362 select a device that allows for the greatest level of programme participation.

363 Although the use of self-sampling devices has been studied primarily to increase uptake by non-responding women
364 [46-52] or specifically targeted at disadvantaged groups due to their socio-economic status or health conditions [53]
365 [54-58], it is already being used as a screening method for the general population in some countries such as the
366 Netherlands [59] and Australia [60]. As recent studies point out [61], although self-sampling may entail a potential
367 loss in sensitivity, this is likely to be offset by the improved effectiveness of the programme resulting from increased
368 acceptance, and it is a more equitable option for women.

369 Lastly, within this new self-sampling model, we must not forget essential aspects in the implementation of
370 population-based screening, such as the use of validated tests [62-63] and the importance of evaluating the results
371 or continuity strategy for follow-up in the case of women with a positive high-risk HPV result.

372 Acknowledgements

373 The authors would like to thank all the women that participated in the study for their time and contributions.
374

375 References

- 376 1. Cancer Today [Internet]. [cited 2022 May 11]. Available from: [https://gco.iarc.fr/today/online-analysis-multi-](https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&)
377 bars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&
378 ex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_
- 380 2. Council of the European Union. Council recommendation of 2 December 2003 of cancer screening
381 (2003/873/EC). *Off.J.Union* 327,34-38; 2003.
- 382 3. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality
383 Assurance in Cervical Cancer Screening. Second Edition—Summary Document. *Ann Oncol*. 2010 Mar
384 1;21(3):448.
- 385 4. Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, et al. Status of implementation and organization of
386 cancer screening in The European Union Member States—Summary results from the second European
387 screening report. *Int J Cancer*. 2018 Jan 1;142(1):44–56.
- 388 5. Abramowitz L, Bernard BC, Stanley M. Cervical cancer prevention policy atlas. Epub. 2020;(January).
- 389 6. Shastri SS, Temin S, Almonte M, Basu P, Campos NG, Gravitt PE, et al. Secondary Prevention of Cervical
390 Cancer: ASCO Resource—Stratified Guideline Update. *JCO Glob Oncol*. 2022 Sep 26;(8):e2200217.
- 391 7. WHO. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO
392 Guidel. 2013;60.
- 393 8. Bhatla N, Singhal S. Primary HPV screening for cervical cancer. *Best Pract Res Clin Obstet Gynaecol*.
394 2020;65:98–108.
- 395 9. Yeh PT, Kennedy CE, De Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: A
396 systematic review and meta-Analysis. *BMJ Glob Heal*. 2019;4(3).
- 397 10. Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, et al. Accuracy of human
398 papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. *Lancet Oncol*.
399 2014 Feb 1;15(2):172–83.
- 400 11. YS C, S M. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy
401 and Clinical Evidence – An Update [Internet]. *Can Agency Drugs Technol Heal*. 2019;1–42.
- 402 12. WHO. WHO recommendations on self-care interventions. *Hum Reprod Program*. 2020;
- 403 13. Gupta S, Palmer C, Bik EM, Cardenas JP, Nuñez H, Kraal L, et al. Self-Sampling for Human Papillomavirus
404 Testing: Increased Cervical Cancer Screening Participation and Incorporation in International Screening
405 Programs. *Front Public Heal*. 2018 Apr 9;6:77.
- 406 14. WHO23. WHO Consolidated Guideline on Self-Care Interventions for Health. Vol. 23, Omega. 2019. 98–107
407 p.
- 408 15. Boletín oficial del estado [Internet]. Available from: [https://www.boe.es/buscar/doc.php?id=BOE-A-2019-](https://www.boe.es/buscar/doc.php?id=BOE-A-2019-6277)
409 6277
- 410 16. Molina-Barceló A, Moreno Salas J, Peiró-Pérez R, Arroyo G, Ibáñez Cabanell J, Vanaclocha Espi M, et al.
411 Desigualdades de acceso a los programas de cribado del cáncer en España y cómo reducirlas: datos de
412 2013 y 2020. *Rev Esp Salud Publica*. 2021;95(1):e1–28.
- 413 17. Organization WH. WHO Guideline on self-care interventions for health and well-being. 2021.
414 <https://www.apa.org/monitor/jan08/recommended>.
- 415 18. Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB. Cervical Cancer Screening
416 Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer. *Int J Womens*
417 *Health*. 2021;13:841–59.
- 418 19. Koivogui A, Levi S, Finkler M, Lewkowicz S, Gombeaud T, Sabate JM, et al. Feasibility of encouraging
419 participation in colorectal cancer screening campaigns by motivating people through the social network,
420 Facebook. *Colorectal Dis*. 2020 Oct 1;22(10):1325–35.
- 421 20. Rees I, Jones D, Chen H, Macleod U. Interventions to improve the uptake of cervical cancer screening
422 among lower socioeconomic groups: A systematic review. *Prev Med (Baltim)*. 2018 Jun 1;111:323–35.
- 423 21. Karjalainen L, Anttila A, Nieminen P, Luostarinen T, Virtanen A. Self-sampling in cervical cancer screening:
424 Comparison of a brush-based and a lavage-based cervicovaginal self-sampling device. *BMC Cancer*.
425

- 426 2016;16(1):1–10.
- 427 22. Polman NJ, de Haan Y, Veldhuijzen NJ, Heideman DAM, de Vet HCW, Meijer CJLM, et al. Experience with
428 HPV self-sampling and clinician-based sampling in women attending routine cervical screening in the
429 Netherlands. *Prev Med (Baltim)*. 2019;125:5–11.
- 430 23. Besó Delgado M, Ibáñez Cabanell J, Molina-Barceló A, Zurriaga Llorens O, Salas Trejo D. ¿Aceptan las
431 mujeres de la Comunidad Valenciana la auto-toma como forma de cribado de cáncer de cérvix? *Rev Esp*
432 *Salud Publica*. 2021;95:1–18.
- 433 24. Nishimura H, Yeh PT, Oguntade H, Kennedy CE, Narasimhan M. HPV self-sampling for cervical cancer
434 screening: A systematic review of values and preferences. *BMJ Glob Heal*. 2021;6(5):1–14.
- 435 25. Organización Mundial de la Salud. Estrategia mundial para acelerar la eliminación del cáncer del cuello
436 uterino como problema de salud pública. *Ops*. 2020;2(2019):1–39.
- 437 26. Chatzistamatiou K, Vrekoussis T, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, Pasentsis K, et al.
438 Acceptability of Self-Sampling for Human Papillomavirus-Based Cervical Cancer Screening. *J Womens*
439 *Health (Larchmt)*. 2020 Nov;29(11):1447–56.
- 440 27. Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for
441 HPV DNA: a systematic review and meta-analysis. *Sex Transm Infect*. 2017 Feb 1;93(1):56 LP – 61.
- 442 28. Wood A, Emery JD, Jenkins M, Chondros P, Campbell T, Wenkart E, et al. The SMARTscreen Trial: a
443 randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase
444 participation in the Australian National Bowel Cancer Screening Program. *Trials*. 2022;23(1):1–14.
- 445 29. Vives N, Farre A, Ibañez-Sanz G, Vidal C, Binefa G, Milà N, et al. Text messaging as a tool to improve cancer
446 screening programs (M-TICS Study): A randomized controlled trial protocol. *PLoS One*. 2021;16(1
447 January):1–12.
- 448 30. Szarewski A, Cadman L, Ashdown-Barr L, Waller J. Exploring the acceptability of two self-sampling devices
449 for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in
450 London. *J Med Screen*. 2009;16(4):193–8.
- 451 31. Bishop E, Katz ML, Reiter PL. Acceptability of Human Papillomavirus Self-Sampling Among a National
452 Sample of Women in the United States. *Biores Open Access*. 2019;8(1):65–73.
- 453 32. Sultana F, English DR, Simpson JA, Brotherton JML, Drennan K, Mullins R, et al. Rationale and design of the
454 iPap trial: A randomized controlled trial of home-based HPV self-sampling for improving participation in
455 cervical screening by never- and under-screened women in Australia. *BMC Cancer*. 2014;14(1):1–11.
- 456 33. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Austin J, et al. Acceptability of unsupervised HPV
457 self-sampling using written instructions. *J Med Screen*. 2006;13(4):208–13.
- 458 34. Sormani J, Kenfack B, Wisniak A, Datchoua AM, Makajio SL, Schmidt NC, et al. Exploring factors associated
459 with patients who prefer clinician-sampling to HPV self-sampling: A study conducted in a low-resource
460 setting. *Int J Environ Res Public Health*. 2022;19(1):1–11.
- 461 35. Bosgraaf RP, Verhoef VMJ, Massuger LFAG, Siebers AG, Bulten J, de Kuyper-de Ridder GM, et al.
462 Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in
463 30,130 women not attending cervical screening. *Int J cancer*. 2015 Feb;136(3):646–55.
- 464 36. McLachlan E, Anderson S, Hawkes D, Saville M, Arabena K. Completing the cervical screening pathway:
465 Factors that facilitate the increase of self-collection uptake among under-screened and never-screened
466 women, an Australian pilot study. *Curr Oncol*. 2018;25(1):e17–26.
- 467 37. Chen SL, Hsieh PC, Chou CH, Tzeng YL. Determinants of women's likelihood of vaginal self-sampling for
468 human papillomavirus to screen for cervical cancer in Taiwan: A cross-sectional study. *BMC Womens*
469 *Health*. 2014;14(1):1–7.
- 470 38. Berg-Beckhoff G, Leppin A, Nielsen JB. Reasons for participation and non-participation in colorectal cancer
471 screening. *Public Health*. 2022 Apr 1;205:83–9.
- 472 39. Crofts V, Flahault E, Tebeu PM, Untiet S, Fosso GK, Boulvain M, et al. Education efforts may contribute to
473 wider acceptance of human papillomavirus self-sampling. *Int J Womens Health*. 2015 Feb 2;7:149–54.
- 474 40. Brewer N, Bartholomew K, Maxwell A, Grant J, McPherson G, Wihongi H, et al. Correction: Comparison of
475 two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un-
476 and under-screened Māori, Pacific and Asian women: Study protocol for a randomised controlled
477 community trial to examine the effect. *BMC Cancer*. 2020;20(1):1–10.
- 478 41. Iqdbashian S, Boveri S, Spolti N, Radice D, Sandri MT, Sideri M. Self-Collected Human Papillomavirus
479 Testing Acceptability: Comparison of Two Self-Sampling Modalities. <https://home.liebertpub.com/jwh>.
480 2011 Mar 15;20(3):397–402.
- 481 42. Richman AR, Brewer NT, Liebman AK, Rinas AC, Smith JS. Optimising human papillomavirus self-testing for
482 high risk women. *Sex Transm Infect*. 2011 Mar;87(2):118–22.
- 483 43. Lack N, West B, Jeffries D, Ekpo G, Morison L, Soutter WP, et al. Comparison of non-invasive sampling
484 methods for detection of HPV in rural African women. *Sex Transm Infect*. 2005;81(3):239–41.
- 485 44. Di Gennaro G, Licata F, Trovato A, Bianco A. Does self-sampling for human papilloma virus testing have the
486 potential to increase cervical cancer screening? An updated meta-analysis of observational studies and
487 randomized clinical trials. *Front Public Heal*. 2022;10.
- 488 45. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened

- 489 women by using HPV testing on self samples: Updated meta-analyses. *BMJ*. 2018;363.
- 490 46. Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al. A randomized controlled trial in
491 non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus
492 testing versus repeat invitation for cervical screening. *J Med Screen*. 2015 Mar;22(1):28–37.
- 493 47. Castle PE, Silva VRS, Consolaro MEL, Kienen N, Bittencourt L, Pelloso SM, et al. Participation in Cervical
494 Screening by Self-collection, Pap, or a Choice of Either in Brazil. *Cancer Prev Res (Phila)*. 2019
495 Mar;12(3):159–70.
- 496 48. Darlin L, Borgfeldt C, Forslund O, Hénic E, Hortlund M, Dillner J, et al. Comparison of use of vaginal HPV
497 self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in
498 organized cervical screening. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2013 Sep;58(1):155–60.
- 499 49. Kitchener H, Gittins M, Cruickshank M, Moseley C, Fletcher S, Albrow R, et al. A cluster randomized trial of
500 strategies to increase uptake amongst young women invited for their first cervical screen: The STRATEGIC
501 trial. *J Med Screen*. 2018 Jun;25(2):88–98.
- 502 50. Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JML, et al. Home-based HPV self-
503 sampling improves participation by never-screened and under-screened women: Results from a large
504 randomized trial (iPap) in Australia. *Int J cancer*. 2016 Jul;139(2):281–90.
- 505 51. Castle PE, Rausa A, Walls T, Gravitt PE, Partridge EE, Olivo V, et al. Comparative community outreach to
506 increase cervical cancer screening in the Mississippi Delta. *Prev Med (Baltim)*. 2011 Jun;52(6):452–5.
- 507 52. Elfström KM, Sundström K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, et al. Increasing participation
508 in cervical screening by targeting long-term nonattenders: Randomized health services study. *Int J cancer*.
509 2019 Dec;145(11):3033–9.
- 510 53. Bansil P, Wittet S, Lim JL, Winkler JL, Paul P, Jeronimo J. Acceptability of self-collection sampling for HPV-
511 DNA testing in low-resource settings: a mixed methods approach. *BMC Public Health*. 2014 Jun;14:596.
- 512 54. Carrasquillo O, Seay J, Amofah A, Pierre L, Alonzo Y, McCann S, et al. HPV Self-Sampling for Cervical Cancer
513 Screening Among Ethnic Minority Women in South Florida: a Randomized Trial. *J Gen Intern Med*. 2018
514 Jul;33(7):1077–83.
- 515 55. Murphy J, Mark H, Anderson J, Farley J, Allen J. A Randomized Trial of Human Papillomavirus Self-Sampling
516 as an Intervention to Promote Cervical Cancer Screening Among Women With HIV. *J Low Genit Tract Dis*.
517 2016 Apr;20(2):139–44.
- 518 56. Reques L, Rolland C, Lallemand A, Lahmidi N, Aranda-Fernández E, Lazzarino A, et al. Comparison of cervical
519 cancer screening by self-sampling papillomavirus test versus pap-smear in underprivileged women in
520 France. *BMC Womens Health*. 2021 May;21(1):221.
- 521 57. Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or
522 the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic
523 groups in France. *Int J cancer*. 2013 Dec;133(11):2681–7.
- 524 58. Kilfoyle KA, Des Marais AC, Ngo MA, Romocki L, Richman AR, Barclay L, et al. Preference for Human
525 Papillomavirus Self-Collection and Papanicolaou: Survey of Underscreened Women in North Carolina. *J*
526 *Low Genit Tract Dis*. 2018 Oct;22(4):302–10.
- 527 59. The National Institute for Public Health and the Environment (RIVM). Framework for the execution of
528 cervical cancer screening. 2021;
- 529 Self-collected vaginal samples. Clinical Guidelines [Internet]. Available from:
530 [https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/management-of-oncogenic-hpv-](https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/management-of-oncogenic-hpv-test-results/self-collected-vaginal-samples)
531 [test-results/self-collected-vaginal-samples](https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/management-of-oncogenic-hpv-test-results/self-collected-vaginal-samples)
- 532 61. Smith MA, Hall MT, Saville M, Brotherton JML, Simms KT, Lew J-B, et al. Could HPV Testing on Self-collected
533 Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. *Cancer*
534 *Epidemiol biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol*. 2021
535 Feb;30(2):268–77.
- 536 62. Arbyn M, Castle PE, Schiffman M, Wentzensen N, Heckman-Stoddard B, Sahasrabudde V V. Meta-analysis
537 of agreement/concordance statistics in studies comparing self- vs clinician-collected samples for HPV
538 testing in cervical cancer screening. *Int J Cancer*. 2022;151(2):308–12.
- 539 63. Tatar O, Haward B, Zhu P, Griffin-Mathieu G, Perez S, McBride E, et al. Understanding the Challenges of
540 HPV-Based Cervical Screening: Development and Validation of HPV Testing and Self-Sampling Attitudes and
541 Beliefs Scales. *Curr Oncol*. 2023;30(1):1206–19.
- 542



Device
A

Device
B

Device
C

Device
D

Device
E

Figure 1






Figure 2

Easy to use Would you use it at home?




Figure 3




Figure 4